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Abstract
The brain’s white matter is highly vulnerable to reductions in cerebral blood flow via mechanisms that may involve
elevated microgliosis and pro-inflammatory pathways. In the present study, the effects of severe cerebral hypoperfusion
were investigated on white matter function and inflammation. Male C57Bl/6J mice underwent bilateral common carotid
artery stenosis and white matter function was assessed at seven days with electrophysiology in response to evoked
compound action potentials (CAPs) in the corpus callosum. The peak latency of CAPs and axonal refractoriness was
increased following hypoperfusion, indicating a marked functional impairment in white matter, which was paralleled by
axonal and myelin pathology and increased density and numbers of microglia/macrophages. The functional impairment in
peak latency was significantly correlated with increased microglia/macrophages. Dimethyl fumarate (DMF; 100 mg/kg), a
drug with anti-inflammatory properties, was found to reduce peak latency but not axonal refractoriness. DMF had no
effect on hypoperfusion-induced axonal and myelin pathology. The density of microglia/macrophages was significantly
increased in vehicle-treated hypoperfused mice, whereas DMF-treated hypoperfused mice had similar levels to that of
sham-treated mice. The study suggests that increased microglia/macrophages following cerebral hypoperfusion contrib-
utes to the functional impairment in white matter that may be amenable to modulation by DMF.
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Introduction
The integrity and connectivity of the brain’s white
matter are critical in regulating efficient neuronal com-
munication and maintaining cognitive function. The
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key functional cellular elements of white matter tracts
are myelinated axons, the integrity of which is depend-
ent on a constant supply of energy to enable accuracy
and speed of action potential conduction between dif-
ferent brain regions.1 Myelinated axons and oligo-
dendrocytes in white matter are highly vulnerable to
reductions in cerebral blood flow.2–4 White matter
hyperintensities, frequently detected in MRI scans
from the brains of elderly individuals and those with
dementia, are closely linked to cerebral hypoperfu-
sion.5,6 A causal relationship has been shown in
mouse models, whereby chronic hypoperfusion leads
to white matter injury as detected using DT-MRI7
and pathological investigations which show impaired
axon-glial integrity and robust microgliosis.8,9
At a functional level, the burden of white matter
hyperintensity load has been correlated with cognitive
deficits.10,11 We have demonstrated that chronic hypo-
perfusion in mice initially induces a selective deficit in
spatial working memory8 that progresses to encompass
deficits in spatial reference memory in the longer term.12
Oxygen-glucose deprivation in ex vivo brain slices
induces an irreversible conduction failure of evoked
compound action potential (CAP) assessed with electro-
physiology in the corpus callosum, which is accompa-
nied by axonal pathology and oligodendrocyte death.13
At a mechanistic level, an elevated inflammatory
response is implicated in the pathogenesis of white
matter pathology following cerebral hypoperfusion.
We have reported increased numbers of microglia in
white matter following mild chronic hypoperfu-
sion8,12,14 which is also observed in more severe
models.15 In white matter, increased levels of cytokines
and chemokines such as TNFa, IL-1b, IL-6 and
MCP116,17 and increased levels of oxidised proteins
and DNA are present following chronic hypoperfu-
sion,18–20 which are both implicated in microglial-
mediated damage.9,21 Pharmacological compounds
that reduce activated microglia and pro-inflammatory
pathways have beneficial effects on white matter after
chronic hypoperfusion22–24 and confer protective effects
against cognitive deficits.25 Similarly, drugs which
reduce pro-inflammatory microglia in white matter
can improve CAP amplitude after traumatic brain
injury (TBI) and experimental autoimmune encephalitis
(EAE; a mouse model of multiple sclerosis).26,27
Dimethyl fumarate (DMF), an anti-inflammatory
drug,28 has neuroprotective effects in a number of
mouse models of neurodegenerative diseases29 which
are paralleled by a reduction in microgliosis.30–32
Similarly, DMF has neuroprotective effects in intracer-
ebral or subarachnoid haemorrhage and focal cerebral
ischaemia33–36 where it can improve neurological def-
icits and reduce microglial activation.35,36 DMF or
monomethyl fumarate (MMF; the active metabolite
of DMF) treatment of microglial cultures can inhibit
lipopolysaccharide-induced production of pro-
inflammatory cytokines and switch the molecular
phenotype of microglia to an alternatively activated,
neuroprotective one.37–39 Of relevance to white matter
damage, DMF has been shown to reduce demyelin-
ation, axonal damage, and improve survival and
disease course in EAE.40–42
The present study aimed to test the hypothesis that
severe hypoperfusion would cause a functional and
structural impairment of white matter and increased
neuroinflammation and that DMF would improve




Adult male C57Bl/6J mice (aged 3–4 months, group
housed, obtained from Charles River UK, 12 h light/
dark cycle, free access to food and water) underwent
severe chronic cerebral hypoperfusion via bilateral
common carotid artery stenosis using microcoils
under isoflurane anaesthesia. A 0.18mm internal diam-
eter microcoil was applied to the left and a 0.16mm
microcoil was applied to the right common carotid
artery as previously described.15 Sham mice underwent
identical surgical procedure except the microcoils were
not placed on the arteries. To assess if hypoperfusion
could induce functional deficit in the corpus callosum
and to determine the pathological correlates, CAPs
were assessed in a cohort of mice using electrophysi-
ology (hypoperfusion n¼ 12, sham n¼ 12). To deter-
mine the effects of DMF on white matter function and
pathology, two experimental cohorts were studied.
Cohort 1 underwent assessment of white matter
pathology (sham vehicle n¼ 7; sham DMF n¼ 8; hypo-
perfused vehicle n¼ 15; hypoperfused DMF n¼ 11).
Cohort 2 underwent electrophysiology and inflamma-
tory-related multiplex analysis (sham vehicle n¼ 10;
sham DMF n¼ 10; hypoperfused vehicle n¼ 16; hypo-
perfused DMF n¼ 13). Group size was determined
using power calculations from electrophysiology data.
Mice were closely monitored following surgery and
those that had a poor recovery after surgery were
culled. The initial and final cohort sizes are indicated
in supplementary Table 1.
In all cohorts, mice were coded and randomly
assigned to experimental groups. Mice were terminated
seven days following surgery. The surgery was under-
taken by an experimenter who was blinded to drug
treatment group. The data analysis was conducted by
researchers blinded to experimental grouping. All
experiments were conducted under the UK Home
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Office Animals (Scientific Procedures) Act 1986, in
agreement with local ethical and veterinary approval
(Biomedical Research Resources, University of
Edinburgh) and the ARRIVE guidelines.
Laser speckle contrast imaging
Details of laser speckle contrast imaging are presented
in the supplemental material.
Administration of DMF
DMF (Sigma, UK) was administered twice daily
(8 a.m. and 5 p.m.) by oral gavage at 100mg/kg body
weight in 0.8% hydroxypropyl methylcellulose (Sigma,
UK) vehicle as previously described.41 Control animals
received vehicle only. Administration of DMF or vehi-
cle began 24 h prior to surgery and continued for seven
days. Investigators administering DMF or vehicle were
blinded as to surgical intervention.
Electrophysiology
Mice were terminated by cervical dislocation followed
by decapitation. Brains were rapidly dissected, placed
in a cell strainer and submerged in ice-cold oxygenated
artificial cerebrospinal fluid (aCSF) (189mM sucrose;
10mM D-glucose; 26mM NaHCO3; 3mM KCl; 5mM
MgCl2, 5; 0.1mM CaCl2; 1.25mM NaH2PO4) for
2–3min. Brains were then affixed to a metal vibratome
plate and placed in a bath of oxygenated ice-cold
sucrose-aCSF. A single 400 mm coronal slice approxi-
mately 1.2–1.7mm from bregma was cut using a
vibratome (Zeiss, Germany), and then transferred to a
warmed incubation chamber (32–35C) containing
oxygenated aCSF (10mM D-Glucose; 26mM
NaHCO3; 5mM KCl; 2mM CaCl2; 124mM NaCl;
1.25mM NaH2PO4; 1.3mM MgSO4). The incubation
chamber was then allowed to return to room tempera-
ture for at least 1 h prior to slice recording.
For recording, individual slices were transferred to
the slice chamber, super-perfused with oxygenated
room temperature aCSF (2–3ml/min), secured with a
slice anchor and allowed to rest for 30min. Recording
electrodes (1–5 M) were pulled from borosilicate glass
capillaries and filled with aCSF, connected to the head-
stage via the Ag/AgCl wire and lowered into the corpus
callosum. A bipolar stimulating electrode was con-
nected to the stimulus isolation unit and lowered into
the corpus callosum. Constant current square wave
pulses were delivered at 0.2Hz for eight sweeps and
the average response of the final four sweeps used for
analysis.43 The data were digitised at 200 kHz,
amplified at 100 and low pass filtered at 5 kHz then
recorded on Clampex 10.3.
CAPs were evoked, whilst holding the stimulus
intensity constant (100ms duration, 0.2Hz), and rec-
orded at 0.5mm increments from 1 to 2.5mm by
moving the recording electrode. The post-stimulus
latency of the CAP peak was then measured as a func-
tional index of conduction velocity. For statistical com-
parison between groups, the CAP was measured at a
distance of 2.5mm apart.
Axonal health can be assessed by assaying changes
in axonal excitability or axonal ‘refractoriness’.43,44 To
assess the axon refractoriness, a single control stimulus
was given followed by a paired pulse of equal intensity
separated by a variable time window decreasing from
10 to 1.5ms in 0.5ms increments. The control ampli-
tude was subtracted from the paired pulse response to
leave only the second pulse which was measured and
normalised to the % of the baseline CAP. The results
were graphed versus the inter-pulse interval, and the
interval that results in a 50% reduction in CAP was
used for statistical comparisons.
Tissue processing and immunohistochemistry
To determine the effects of severe hypoperfusion on
white matter function and pathology, one cohort
underwent electrophysiology, and an adjacent 2mm
slice of tissue was processed for paraffin embedding,
then 8 mm sections were cut with a microtome. All
other mice were deeply anesthetized with 5% isoflurane
and transcardially perfused with 20ml of 0.9% hepar-
inized phosphate buffer saline (PBS) and then 20ml of
4% paraformaldehyde (PFA) in 0.9% PBS seven days
after surgery. After perfusion, brains were removed,
postfixed in 4% PFA for 24 h and then transferred to
30% sucrose in PBS for 48 h. Brains were frozen in
isopentane at 42C for 2min. Thirty micrometres cor-
onal sections were cut using a cryostat (Leica) and
stored in cryoprotective medium (30% glycerol/30%
ethylene glycol in phosphate buffer) at 20C until
use. Cryostat sections were dehydrated through an
increasing alcohol series, and then immersed in xylene
for 10min before being rehydrated through a decreas-
ing alcohol series. Sections were then equilibrated in
PBS for 5 min before antigen retrieval (if required). A
10 mM citric acid (pH 6) antigen retrieval was carried
out for Iba1, MBP and MAG staining. Sections were
blocked using 10% normal serum and 0.5% BSA for
1 h at room temperature. Primary antibodies were made
up in blocking solution and sections were incubated in
primary antibody at 4C overnight. The following day,
the sections were incubated with secondary antibody
in PBS for 2 h at room temperature. Coverslips were
mounted using Vectashield HardSet mounting medium
with or without DAPI. The following primary antibo-
dies were used in the study: antimyelin-associated
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glycoprotein (MAG) (1:200, Abcam) as an index of
axon-glial integrity; anti-myelin basic protein (MBP)
to label myelin (1:100, Millipore); anti-ionised
calcium-binding adaptor receptor molecule 1 (Iba1) to
label microglia (1:100, Menarini); antiamyloid precur-
sor protein (APP) to label axonal damage (1:200,
Millipore); antiadenomatous polyposis coli protein
CC1 (APC) to label oligodendrocyte cell bodies
(1:200, Calbiochem); antineuronal-glial antigen (NG2)
to label oligodendrocyte progenitor cells (1:100,
Millipore). Alexa Fluor 488 and 555 conjugated sec-
ondary antibodies (1:500) were purchased from Life
Technologies Ltd (UK).
Image acquisition and analysis
All images were acquired using a confocal microscope
(Leica TCS SP5) with either a 20 air or a 40 oil-
immersion objective, pinhole of 1 Airy unit and
1024 1024 pixel resolution. MBP, MAG, APP, and
Iba1 immunostainings were acquired as one single
image, while CC1 and NG2 were acquired as a 5 mm
stack. Images were acquired at the corpus
callosum from the right hemisphere above the lateral
ventricle at the stereotactic co-ordinates, lateral
2.40 0.1mm, Bregma 1.5 0.1mm. Quantitative
measurements were performed using imageJ (FIJI) soft-
ware. The number of Iba-1 positive cells was counted in
three defined areas, and the average was used for statis-
tical purposes.Mean fluorescence intensity (MBP,MAG
immunostaining) or the percentage area of positive stain-
ing (Iba1 immunostaining) or number of cells/volume
(CC1/NG2 immunostaining) were measured at the
corpus callosum which was manually outlined using a
free-hand tool. The number of swollen axons (axonal
bulbs) in APP immunostained sections was counted in
three defined areas along the corpus callosum and the
average was used for statistical purposes. Observers
were blind to surgery procedure and drug treatment.
Inflammatory-related protein multiplex
Brain homogenates were assayed for inflammatory-
related molecules using a Bio-plex mouse cytokine
and chemokine assay (Biorad), which allows the detec-
tion of multiple inflammatory-related molecules in the
same sample. A 1.8mm section rostral to the brain slice
used for electrophysiology was snap frozen in liquid
nitrogen and stored at 80C. Tissue was weighed
and homogenised in 5 volume of tissue lysing solu-
tion (Bioplex cell lysis kit, made according to manufac-
turer’s instructions), and then sonicated for 5 s at 10%
amplitude. Samples were spun at 5000 g at 4C, and
then the supernatant was collected and stored at
80C. Total protein concentration was determined
using a Thermo Scientific Pierce BCA Protein Assay
Kit and samples were diluted with bioplex cell lysis
buffer to obtain a final total protein concentration of
13mg/ml. Samples were then diluted to 8mg/ml in bio-
plex sample buffer diluent before they underwent the
multiplex assay according to the manufacturer’s
instructions. The levels of seven inflammatory-related
molecules were measured: interleukin-6 (IL-6), interleu-
kin-1b (IL-1b), interferon-g (IFN-g), keratinocyte
chemoattractant (KC), monocyte chemoattractant-1
(MCP-1), macrophage inflammatory protein 1-a
(MIP-1a) and vascular endothelial growth factor
(VEGF) in duplicate with standards (sham vehicle
n¼ 8; sham DMF n¼ 8, hypoperfused vehicle n¼ 11;
hypoperfused DMF n¼ 11). One animal from each of
the hypoperfusion groups and two animals from each
of the sham groups were randomly selected for omis-
sion from this experiment due to the space restrictions
of the 96-well plate. Standards included in each kit were
used to generate standard curves for each analyte, and
then the mean fluorescence intensity for each analyte
was calculated with five-point logistic regression using
Bio-plex workstation software (Biorad).
Statistics
Analysis and graphs were generated using
Prism GraphPad 5.0 software. Data from the electro-
physiology and related pathology cohorts were
normally distributed and analysed using Student’s t
test for independent samples. Associations between
electrophysiology data and microglia numbers were
analysed with Pearson’s correlation analysis. Other
data, in which the effect of surgery and drug treatment
or cerebral blood flow were investigated, were analysed
by two-way analysis of variance (ANOVA) followed by
Bonferroni post hoc test. Data were expressed as
mean standard error of the mean and considered stat-
istically significant when p-value was <0.05.
Results
Hypoperfusion induces severe reductions
in cerebral blood flow
To determine if hypoperfusion induced reductions in
cerebral blood flow, laser speckle contrast imaging was
used one and seven days following surgery (supplemen-
tal Figure 1(a)). There was a significant effect of surgery
(F(1-18)¼ 58.2; p< 0.0001) and of time (F(2, 36)¼ 51.6;
p< 0.0001) in the CBF values (% of baseline).
Post hoc analysis showed that there is a significant
reduction in CBF in hypoperfused mice compared with
sham-treated mice 24 h (p< 0.001) and seven days fol-
lowing surgery (p< 0.001) (supplemental Figure 1(b)).
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Severe hypoperfusion induces a deficit in white
matter function
At the outset, the effects of severe hypoperfusion on
white matter function at seven days were assessed by
electrophysiology in the corpus callosum. The peak
latency of evoked CAPs, as an index of conduction
velocity, was significantly increased in hypoperfused
by 17% 3.6% as compared to sham mice (p¼ 0.003)
(Figure 1(a) and (b)). As a measure of axonal health,
axonal refractoriness of CAPs was studied in the corpus
callosum. The interpulse interval resulting in a 50%
reduction in the CAP was significantly increased in
hypoperfused mice, indicative of perturbed axonal
health (p¼ 0.03) when compared with sham-treated
animals (Figure 1(c) and (d)). Collectively, these data
indicate that callosal white matter fibres exhibit pro-
nounced alterations in their electrophysiological prop-
erties in response to severe hypoperfusion.
Increased white matter pathology and inflammation
in response to severe hypoperfusion
To determine if the deficit in white matter function was
accompanied by pathological changes to myelinated
axons and an inflammatory response, the adjacent
slices to those used for electrophysiology were assessed.
There was a significant reduction in the % area of MBP
staining following hypoperfusion, indicating that
hypoperfusion caused myelin pathology (p¼ 0.016;
Figure 2(a) and (b)). Axonal bulbs, detected with
APP immunohistochemistry, were not present in
sham-treated animals but were significantly increased
in hypoperfused animals (p¼ 0.001; Figure 2(c) and
(d)), thus indicating that hypoperfusion caused axonal
pathology.
Iba-1-positive immunostaining was undertaken in
the corpus callosum to investigate the impact of
hypoperfusion on inflammation (Figure 3(a)). There
was a significant increase in the number of Iba1-
positive cells (p¼ 0.0003; Figure 3(b)) and the density
of Iba1-immunostaining (p¼ 0.009; Figure 3(c))
following hypoperfusion. A number of studies have
indicated that pharmacological drugs which reduce
microglia in white matter can improve conduction
velocity,26,27 suggesting that increased microglia may
cause white matter dysfunction. We investigated this
by correlating microglia/macrophages with peak
latency or axonal refractoriness. There was a sig-













































































Figure 1. Deficits in white matter function in response to severe chronic hypoperfusion in myelinated fibres. (a, b) There was a
significant increase in peak latency at 2.5 mm from the stimulating electrode (**p¼ 0.003), indicative of slowed conduction of mye-
linated fibres, in hypoperfused animals. (c, d) For axonal refractoriness, the interpulse interval resulting in a 50% reduction in the CAP
was significantly reduced in hypoperfused mice, indicative of perturbed axonal health. (*p¼ 0.03), when compared with sham-treated
animals. Data are presented as mean S.E.M. Student’s t test, *p< 0.05 **p< 0.01, n¼ 12 per group.
1358 Journal of Cerebral Blood Flow & Metabolism 38(8)
of microglia and slowing of peak latency (r¼ 0.59,
p¼ 0.002; Figure 3(d)) and density of Iba-1 immunos-
taining and slowing of peak latency (r¼ 0.55,
p¼ 0.006; Figure 3(e)), thus indicating an association
between microglia/macrophages and deficits in con-
duction velocity. There was no significant association
between microglial/macrophage numbers and slowing
of axonal refractory period (r¼ 0.4, p¼ 0.06; Figure
3(e)) or microglial/macrophage density and slowing
of axonal refractory period (r¼ 0.29, p¼ 0.17;
Figure 3(g)).
DMF treatment improves white matter function
following severe hypoperfusion
To further investigate the hypothesis that microglia
can cause white matter dysfunction, a drug which is
known to reduce microglial activation, DMF,36 was
investigated to determine if it could protect improve
white matter function following hypoperfusion. DMF
significantly reduced the peak latency in hypoperfused
mice by 7% 1.2% of vehicle-treated hypoperfused
mice control values (p< 0.05) (Figure 4(a) and (b)).
Thus, the data indicate a beneficial effect of DMF on
conduction velocity of myelinated fibres. Axonal refrac-
toriness was not significantly altered by DMF treat-
ment (p¼ 0.07) (Figure 4(c) and (d)). Therefore, these
data indicate that callosal white matter fibres exhibit
pronounced alterations in conduction velocity and
that DMF treatment can improve white matter
function.
Hypoperfusion causes a breakdown of axon-glial
integrity that is unaffected by DMF
Following the demonstration that DMF improved
white matter function in hypoperfused mice, its
impact on hypoperfusion-induced pathology to myelin-
ated axons was explored.MBP, a marker of myelin integ-
rity, was not significantly altered in response to
hypoperfusion or DMF administration (Figure 5(a) and
(b)). Therefore, a further marker of myelin damage was
investigated, MAG, as reductions inMAG intensity have
been demonstrated previously in response to hypoperfu-
sion, indicative of altered axon-glial integrity.9,14 A
significant reduction inMAG immunostaining was deter-
mined following severe hypoperfusion (F(1-33)¼ 11.7;
p¼ 0.002), but there was no significant effect of DMF
administration or interactions (Figure 4(c) and (d)).
Post hoc comparison showed a significant reduction in
MAG immunostaining with hypoperfusion in both vehi-
cle- (p< 0.05) and DMF-treated (p< 0.05) groups when
compared with sham controls.
Previous studies have revealed differential vulner-
abilities of mature oligodendrocytes and their precursor
cells in response to hypoperfusion. Oligodendrocytes
have been suggested to facilitate axonal conduction
by mechanisms other than myelination.45 Thus, the
numbers of these cells were determined after hypoper-
fusion and DMF treatment using CC1 and NG2 immu-
nohistochemistry for mature oligodendrocytes and
OPCs, respectively (Figure 5(e)). Although there was





















































Figure 2. White matter pathology in response to severe chronic hypoperfusion. (a) Confocal images from the corpus callosum of
animals immunostained with MBP (red), scale bar: 50 mm. (b) There was a significant reduction in the % area of MBP immunostaining
following hypoperfusion (*p¼ 0.016). (c) Confocal images from the corpus callosum of animals immunostained with APP (green), scale
bar: 50mm. (d) There was a significant increase in axonal damage following hypoperfusion (***p¼ 0.001).
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cells (F(1-31)¼ 13.0, p¼ 0.001) in response to hypoper-
fusion, DMF treatment had no effect and there were no
significant interactions (Figure 4(f)). Post hoc compari-
son indicated a significant reduction in the number of
CC1 immunopositive cells following hypoperfusion
in DMF-treated mice (p< 0.05) but not in vehicle-
treated mice (p> 0.05). In contrast, there was a sig-
nificant increase in the number of NG2-positive cells
(F (1-33)¼ 7.6, p¼ 0.009); however, DMF treatment
had no significant effect on the number of NG2
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Figure 3. Elevated microglia/macrophage number and density in response to severe chronic hypoperfusion. (a) Confocal images
from the corpus callosum of animals immunostained with Iba1 (green), scale bar: 50 mm. (b) There was a significant increase in
microglial numbers following hypoperfusion (***p¼ 0.0003). (c) There was a significant increase in % area of Iba1 immunostaining
following hypoperfusion (**p¼ 0.009). (d) There was a significant positive correlation between numbers of microglia and slowing of
peak latency (r¼ 0.59, p¼ 0.002). (e) There was a signification positive correlation between % area of Iba1 immunostaining and peak
latency (r¼ 0.55, p¼ 0.006). (f) There was no significant association between microglial numbers and slowing of axonal refractory
period (r¼ 0.4, p¼ 0.06) (g) and no association between % area of Iba1 immunostaining and peak latency (r¼ 0.29, p¼ 0.17). Data are
presented as mean S.E.M. Student’s t test, *p< 0.05 **p< 0.01, ***p< 0.001; n¼ 12 per group.
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To build on the previous findings that axonal health
was impaired by hypoperfusion but axonal refractori-
ness was not modulated by DMF, axonal pathology
was investigated by APP immunostaining and assess-
ment of the number of APP-positive axonal bulbs
(Figure 5(g)). Axonal bulbs were not detected in sham
mice but were observed in hypoperfused mice in the
corpus callosum. There was a significant increase in
the number of APP-positive axonal bulbs after hypo-
perfusion surgery (F(1-33)¼ 4.9, p¼ 0.04), but the
number was unaffected by DMF and there were no
significant interactions (Figure 5(h)).
Thus, although hypoperfusion causes damage to
myelinated axons, axon-glial integrity and the number
of mature and immature oligodendrocytes, these meas-
ures were unaffected by DMF.
Hypoperfusion increased microglial/macrophage
density which is modulated by DMF
Previous studies have indicated that DMF may exert
protective effects through inflammatory mechan-
isms.32,36 Since we found a significant association
between microglia/macrophages and deficits in white
matter function, we next determined if microglial/
macrophages would be affected by DMF treatment
(Figure 6(a)). Microglial/macrophage density was
significantly increased following hypoperfusion
(F(1-33)¼ 7.93, p¼ 0.008), but there was no effect of
drug treatment (Figure 6(b)). Notably, post hoc ana-
lysis showed that there was a significant increase in Iba1
staining in hypoperfused vehicle-treated mice compared
with sham vehicle-treated mice (p< 0.05), but there was
no difference between sham and hypoperfused mice
treated with DMF (p> 0.05), suggesting that DMF
modestly reduced the density of microglia/
macrophages.
Hypoperfusion and DMF treatment effects
on cytokines, chemokines and growth factors
The modest reduction in the microglial/macrophage
response to hypoperfusion with DMF treatment sug-
gested that DMF may act by modulating levels of
inflammatory-related proteins. To further explore neu-
roinflammatory mechanisms, a range of cytokines, che-
mokines and growth factors were examined using a
multiplex immunoassay.
The levels of chemoattractant and growth factor
molecules MIP-1a, MCP-1, KC and VEGF were exam-
ined firstly (Figure 7). All four molecules were signifi-
cantly increased after hypoperfusion (MIP-1a F(1-34)¼
13.7, p¼ 0.0008; MCP-1F(1-34)¼ 18.2, p¼ 0.0001; KC



















































































Figure 4. DMF treatment improved the peak latency of CAP, but not axonal refractoriness following severe chronic hypoperfusion.
(a, b) DMF-treated hypoperfused mice had a reduced peak latency compared to vehicle-treated mice (*p< 0.05) indicating that DMF is
able to improve conduction velocity of myelinated fibres. (c, d) Axonal refractoriness was not significantly altered by DMF treatment
(p¼ 0.07). Data are presented as mean S.E.M. Student’s t test, *p< 0.05 n¼ 12 per group.




































































































































Figure 5. Axon-glial integrity was damaged by severe hypoperfusion but unaffected by DMF administration. (a) Confocal images
from the corpus callosum of animals from four experimental groups immunostained with MBP (red), scale bar: 50 mm. (b)
Quantification of MBP immunostaining sections showing no significant changes in myelin among the groups. (c) Confocal images from
the corpus callosum of animals from four experimental groups immunostained with MAG (green), scale bar: 50mm. (d) MAG
immunostained sections showing changes in myelin in hypoperfused animals. Quantification of MAG mean intensity shows an overall
significant effect of surgery (F(1-31)¼ 11.7; **p¼ 0.002) Post hoc comparison shows a significant reduction with hypoperfusion in both
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p< 0.0001), and there was no significant effect of DMF
administration or significant interactions. Post hoc
comparison showed a significant increase in the levels
of MCP-1, KC and VEGF in hypoperfused vehicle-
treated mice compared with sham vehicle-treated mice
and in DMF hypoperfused compared to DMF sham-
treated mice. In contrast, although MIP-1a levels were
significantly increased (p< 0.01) in hypoperfused vehi-
cle-treated mice compared with sham vehicle-treated
mice, MIP-1a levels in DMF-treated hypoperfused
mice were not significantly different compared with
sham DMF-treated mice (p> 0.05) suggesting that
DMF reduced levels of MIP-1 a (Figure 7(a)).
Three cytokines were examined, IL-6, IL-1b and
IFN-g (Figure 7). IL-6 levels were significantly
increased after hypoperfusion (F(1-34)¼ 4.4, p¼ 0.04)
but unaffected by DMF treatment, and there were no
significant interactions (Figure 7(e)). IL-1 b and IFN-g
were unaffected by hypoperfusion surgery or DMF
treatment (Figure 7(f) and (g)).
Therefore, overall analyses indicated hypoperfusion
had a prominent effect on inflammatory-related mol-
ecules which was unaffected by DMF treatment
except for MIP 1a levels which were dampened by
DMF treatment.
Discussion
The present study demonstrated that severe hypoperfu-
sion induces a deficit in white matter function in the
corpus callosum which is correlated with a marked
increase in microglia/macrophages. Treatment with an
anti-inflammatory drug, DMF, improved white matter
function and dampened microglial/macrophage density
induced by severe hypoperfusion.
White matter function assessed with electrophysi-
ology was markedly impaired in the corpus callosum,
key tracts connecting cerebral hemispheres and vulner-
able to damage following chronic hypoperfusion.8,15
The assessment of evoked CAPs has been used in a
number of other studies to demonstrate that perturb-
ations in white matter can impact their function. For
example, deficits in white matter function have been
detected by measuring CAP in response to oxygen glu-
cose deprivation,46–48 TBI49 and excitotoxicity.50 This
approach is very sensitive to the electrophysiological
properties of white matter and can be used to detect
altered function caused by subtle alterations of white
matter such as differing effect of sex hormone on recov-







































Figure 6. The effect of DMF on the microglial response. (a)
Confocal images from the corpus callosum from four experi-
mental groups. Green: Iba1; Scale bar: 50mm. (b) There was a
significant effect of surgery (F (1-33)¼ 7.9; **p¼ 0.008) in the %
area of Iba1 immunostaining. Notably, post hoc analysis showed
that there is a significant increase in Iba1 staining in hypoperfused
vehicle treated mice compared with sham vehicle treated mice
(#p< 0.05), but no difference between sham and hypoperfused
mice treated with DMF (p> 0.05). Data are presented as
mean SEM, Two-way ANOVA followed by Bonferroni post hoc
test, sham vehicle n¼ 7; sham DMF n¼ 8; hypoperfusion vehicle
n¼ 13; hypoperfusion DMF n¼ 9.
Figure 5. Continued
vehicle (#p< 0.05) and DMF treated (#p< 0.05) groups. (e) Confocal images from the corpus callosum from four experimental groups
immunostained for markers of mature oligodendrocytes (CC1) and oligodendrocyte precursor cells (NG2). Green: CC1; red: NG2,
blue: DAPI, scale bar: 100mm. (f) There is a significant reduction in the number of CC1 cells following hypoperfusion (F(1-33)¼ 13.0;
**p¼ 0.001) Post hoc comparison shows a significant reduction in the number of CC1 immunopositive cells following hypoperfusion in
DMF-treated mice (#p< 0.05) but not in vehicle-treated mice (#p> 0.05). There was significant increase in NG2-positive cells
following hypoperfusion surgery (F(1-33)¼ 7.6; **p¼ 0.009). (g) APP-immunostained sections showing axonal damage in hypoperfused
animals while minimal immunostaining is detected in shams. Green: APP. Scale bar: 50 mm. (h) Quantification of axonal bulbs shows an
overall significant effect of surgery (F(1-33)¼ 4.9; *p¼ 0.04). Data presented as mean SEM, Two-way ANOVA followed by Bonferroni
post hoc test, sham vehicle n¼ 7; sham DMF n¼ 8; hypoperfusion vehicle n¼ 13; hypoperfusion DMF n¼ 9.





































































































































































Figure 7. The effect of DMF on chemokines, growth factors and cytokines. Levels of inflammatory-related proteins were calculated
(pg/ml) using a multiplex assay. (a) There was a highly significant effect of surgery (F (1-34)¼ 13.7; ***p¼ 0.0008) in the concentration of
MIP-1a (pg/ml). Post hoc analysis showed that there was a significant increase in MIP-1a levels in hypoperfused vehicle-treated animals
compared with sham vehicle-treated animals (##p< 0.01); however, notably there was no significant increase in MIP-1a levels in the
DMF-treated hypoperfused mice compared with the DMF-treated sham mice (p> 0.05). (b) There was a highly significant effect of
surgery (F (1-34)¼ 18.2; ***p¼ 0.0001) in the concentration of MCP-1 (pg/ml). Post hoc analysis showed that there was a significant
increase in MCP-1 levels in hypoperfused vehicle-treated animals compared with sham vehicle-treated animals (##p< 0.01) and a
significant increase in MCP-1 levels in hypoperfused DMF-treated animals compared with sham DMF-treated animals, but by a lesser
magnitude (#p< 0.05). (c) There was a significant effect of surgery (F (1-33)¼ 14.3; ***p¼ 0.0006) in the concentration of KC (pg/ml).
Post hoc analysis showed that there was a significant elevation in KC levels following hypoperfusion vehicle compared with sham
vehicle treatment (#p< 0.05), and in hypoperfused DMF-treated mice when compared with sham DMF-treated mice (#p< 0.05). (d)
There was a highly significant effect of surgery (F (1-34)¼ 34.8; ***p< 0.0001) in the concentration of VEGF (pg/ml). Post hoc analysis
showed that there was a significant increase in VEGF levels in hypoperfused vehicle-treated animals compared with sham vehicle-
treated animals (##p< 0.01). Notably, there was also a significant increase in VEGF levels in the DMF-treated hypoperfused mice
compared with the DMF-treated sham mice, by a greater magnitude (###p< 0.001) than the increase seen in vehicle treated mice. (e)
For IL-6 levels, there was a significant effect of surgery (F (1-34)¼ 4.4, *p¼ 0.04). (f and g) There was no significant effect of
hypoperfusion or DMF for IL-1b (f) or for IFN-g (g). Data are presented as mean SEM, two-way ANOVA followed by Bonferroni
post hoc test, sham vehicle n¼ 8; sham DMF n¼ 8; hypoperfusion vehicle n¼ 11; hypoperfusion DMF n¼ 11.
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The deficits in white matter function induced by
hypoperfusion included a slowing of peak latency of
CAP, indicative of slowed conduction velocity.
Conduction velocity is the rate at which a nerve impulse
is propagated, and is dependent on normal myelination.
Similar slowing of conduction velocity has been demon-
strated following low-level blast trauma,54 demyelin-
ation44 and neonatal hyperoxia.55 We also
demonstrated that severe hypoperfusion increased the
axonal refractory period, indicative of perturbed axonal
health. Increased refractory period has been reported
after hypoxia in spinal cord; however, this could be recov-
ered following re-oxygenation, suggesting that hypoxia
may be a key mechanism of increased refractoriness fol-
lowing hypoperfusion.56Demyelination of axons induced
by cuprizone or TBI and compression injury also cause
increases in refractoriness.44,49,57,58
Severe hypoperfusion resulted in white matter path-
ology, including myelin and axonal damage detected
with MBP and APP immunohistochemistry that may
account for the deficits in white matter function. This is
an agreement with other studies where structural alter-
ations in white matter are reported to underlie func-
tional alterations. For example, demyelination or
myelin thinning and axonal damage, detected with elec-
tron microscopy or APP immunohistochemistry, are
present in white matter following cuprizone demyelin-
ation, TBI or excitotoxicity which resulted in reduced
CAP amplitude, conduction velocity and increased
refractoriness.43,44,49,50,57
We found a significant elevation in microglia/macro-
phages in the corpus callosum following severe
hypoperfusion. Microglial activation is a robust
response to reduced cerebral blood flow following
chronic hypoperfusion8,14 and in stroke models.59,60
Furthermore, there was a positive correlation between
microglia/macrophages and slowing of peak latency,
suggesting that the elevated inflammatory environment
in myelinated axon tracts may contribute to the func-
tional deficit. Increased microglial levels are also
reported in white matter that exhibit deficits in conduc-
tion velocity or refractoriness following cuprizone
demyelination,44 EAE61 or TBI.58 The extent of
axonal damage in demyelinating MS lesions is asso-
ciated with increased numbers of activated microglia/
macrophages62 which have been hypothesised to play a
mechanistic role in white matter damage through the
release of inflammatory-related mediators such as nitric
oxide, which can induce reversible conduction block
and axonal degeneration in demyelinated axons.63
To further test the hypothesis that microglia may
mediate the deficits in white matter function, we used
a drug, DMF, which is known to reduce microgliosis in
a number of disease models including focal cerebral
ischaemia.36,64 DMF was found to significantly
improve peak latency following severe hypoperfusion.
This corroborates with other studies which have shown
that DMF can exert protective effects on motor and
neurological function in focal cerebral ischaemia,36,64
intracerebral haemorrhage35 and other models of
neurodegeneration.29,31,32,41,65 DMF is also known to
protect against cognitive deficits assessed in the Morris
water maze in a mouse model of subarachnoid haem-
orrhage.34 MMF (derivative of DMF) protects against
functional deficits assessed with electrophysiology in
retinal ischaemia-reperfusion66 and in an experimental
autoimmune neuritis model.65
Although DMF exerted protective effects on white
matter function in the corpus callosum, this was not
paralleled by protective effects on white matter struc-
ture. In a first cohort, reduced MBP immunostaining
was determined in mice that exhibited functional def-
icits following hypoperfusion, confirming the findings
of Miki et al.15 in severe hypoperfusion. However, in a
second cohort, a similar reduction in MBP staining was
not found. The reasons for these differences between
cohorts are not clear. One explanation may be that
the tissue was processed differently using sucrose treat-
ment and cryostat sectioning as opposed to paraffin
embedding. To further examine myelin integrity after
hypoperfusion, we therefore used another marker,
MAG which we previously demonstrated to be sensitive
to chronic hypoperfusion.9,14 However, despite the
reductions in MAG immunostaining in response to
severe hypoperfusion, MAG pathology was not attenu-
ated with DMF. Oligodendrocytes contain a number of
ion channels and neurotransmitter receptors which
monitor neuronal activity and facilitate axonal conduc-
tion by mechanisms other than myelination.45
Therefore, in light of the fact that DMF did not modu-
late MAG pathology, we examined the effects of DMF
on mature and immature oligodendrocyte populations.
We demonstrated that mature oligodendrocytes are
particularly vulnerable to hypoperfusion with levels
markedly reduced seven days following hypoperfusion.
This finding is in agreement with our previous study14
and that of others18 indicating CC1 levels are reduced
within days following chronic hypoperfusion and focal
cerebral ischemia.67,68 In contrast, the levels of NG2
oligodendrocyte cells were increased in response to
severe hypoperfusion, as others69 have reported follow-
ing focal cerebral ischaemia. However, there was no
protective effect of DMF administration on
oligodendrocyte numbers after hypoperfusion.
Similarly, DMF has no protective effects on mature
and oligodendrocyte precursor cells following cupri-
zone demyelination.70
Collectively, the data indicate that DMF can
improve white matter function following hypoperfu-
sion, but this is not associated with a concomitant
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protective effect on axonal-glial integrity. A multitude
of factors contribute to conduction velocity along mye-
linated fibres which also include the distribution and
density of ion channels at nodal regions. Other studies
have showed that deficits in conduction velocity and
axonal refractoriness are sustained in the recovery
from neonatal hyperoxia or withdrawal from cuprizone
diet,44,55 despite a recovery of axon-glial integrity.
Instead, they found sustained, subtle alterations in the
structural composition of the paranode and Node of
Ranvier including increased spread of Nav1.6 channels
along the Node of Ranvier, which we have also
reported after mild chronic hypoperfusion.9
Clofazimine, a drug which prevents loss of potassium
channels, can improve conduction velocity and axonal
refractoriness following TBI.58 Therefore, the limited
exploration of axon-glial integrity that we have carried
out may not be the most sensitive pathological indices
of functional deficits, and instead specific regions of
node and paranodal domains of myelinated axons
and ion channels may be vulnerable.
An important consideration of the present study is
whether the dose of DMF was appropriate to ensure
maximal protective effects in white matter. Protective
effects of DMF have been reported at doses as low as
15mg/kg in intracerebral/subarachnoid haemorrhage
and EAE33,34,40 and 30mg/kg in a model of
Huntington’s disease.29 More recently, Schulze-Topoff
et al.42 used the same dose as the present study
(100mg/kg) to demonstrate clinical and histological
protection following EAE. DMF is thought to act
mechanistically by enhancing the activity of Nrf2 sig-
nalling, an endogenous survival pathway with anti-oxi-
dant and anti-inflammatory effects. Nrf2 is a
transcription factor that activates a battery of cytopro-
tective genes such as genes encoding heme-oxygenase-1
(hmox1), osgin 1 (osgin 1) and NAD(P)H dehydrogen-
ase quinone 1 (nqo1). Brennan et al.71 recently carried
out an investigation of the dose–response effect of
DMF on Nrf2-dependent gene changes. For many
genes studied, such as hmox1, there were no notable
increases in the brain following 100mg/kg of DMF;
however, 400 and 600mg/kg could induce increases in
hmox1 expression, an effect reported by others.32
Therefore, it may be possible that the modest protective
effects that DMF (100mg/kg) had on white matter
function in the present study could be enhanced with
a higher dosage.
In contrast to the protective effects of DMF on peak
latency, we found no parallel protective effects on
axonal refractoriness, as an index of axonal health.
Similarly, we found a significant increase in APP immu-
nostaining, indicative of axonal damage, following
severe chronic hypoperfusion that was not attenuated
with DMF treatment. Similar results were reported on
white matter function following administration of the
immunophilin ligand FK506 after TBI. FK506 treat-
ment could protect against deficits in CAP amplitude,
but did not reduce refractory changes in myelinated
fibres.72 DMF has been reported to protect against
axonal damage detected with APP immunohistochem-
istry in EAE41 and EAN;73 however, this may reflect a
different disease mechanism.
Although we did not detect protective effects of
DMF on hypoperfused-induced damage to myelinated
axons, we found that DMF led to modest reductions in
the extent of microglial/macrophage density. There is a
marked reduction in microglial levels in vivo following
DMF treatment in a mouse model of synucleinopathy32
and Parkinson’s disease.31 Of relevance to the current
study, DMF was found to significantly reduce micro-
glial levels following focal cerebral ischaemia,36 an
effect that was paralleled by reduced cytokine levels.64
In support of our hypothesis that reductions in micro-
glia/macrophages can improve white matter function,
HDAC inhibition or the sodium channel blocker safi-
namide reduced pro-inflammatory microglia/macro-
phages and improved CAP amplitude in the corpus
callous following TBI or EAE.26,27 One limitation of
the current study is that the Iba-1 immunostaining
cannot discriminate between macrophages and brain-
derived microglia; therefore, some of the immunostain-
ing may represent infiltration of peripheral-derived
macrophages. Indeed, transient blood–brain barrier
disruption has been reported in white matter in a rat
model of chronic cerebral hypoperfusion74 and may
contribute to the functional deficit in the present
study. In support of this, it has been reported that
DMF can protect the blood–brain barrier following
focal cerebral ischaemia in the mouse75 via decreased
matrix metalloproteinase activity and protection of
interendothelial tight junctions, resulting in reduced
brain oedema. This raises the possibility that the bene-
ficial effects of DMF on white matter function that we
have reported may have been partly mediated through
protection of the blood–brain barrier, particularly
given the modest effects of DMF on inflammation
that we found.
DMF has been shown to inhibit microglial inflam-
mation in vitro and to suppress the expression of pro-
inflammatory cytokines.76 Therefore, to further investi-
gate the modulation of inflammatory-related proteins
after severe hypoperfusion and DMF treatment, a
panel of molecules were investigated with multiplex.
The chemoattractant molecules MIP-1a (CCL3) and
MCP-1 (CCL2) are both upregulated in the present
study, and are also upregulated in response to focal
cerebral ischaemia and chronic hypoperfusion.77–79
These chemokines regulate the infiltration of mono-
cytes/macrophages into the CNS under pathological
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conditions and are associated with exacerbating neur-
onal damage,80 whereas their inhibition protects neu-
rons.81 We have reported that MIP-1a levels are
modestly dampened following DMF administration,
and this may contribute to the protective effect of
DMF on white matter function, possibly via effects
on monocyte/macrophage infiltration from the periph-
ery. Lin et al.64 reported that DMF reduced the number
of MPOþneutrophils and CD3þT cells which
infiltrated the penumbral region following focal cere-
bral ischaemia.
Levels of the growth factor VEGF were increased in
response to severe chronic hypoperfusion. VEGF is
associated with protective effects following focal cere-
bral ischaemia and chronic cerebral hypoperfusion,
including neuroprotection, increased angiogenesis and
cerebral blood flow.82,83 Of interest, Wiesner et al.84
showed that VEGF levels are elevated in astrocyte cul-
tures treated with DMF, mediated by Nrf2 signalling.
Of the three cytokines that were assessed in the cur-
rent study, only IL-6 was found to be significantly
increased seven days following chronic hypoperfusion.
IL-6 is reported to have both pro- and anti-inflamma-
tory effects;85 however, in the context of cerebral hypo-
perfusion, it confers neuroprotective effects.86
However, we did not find evidence that DMF altered
IL-6 levels. In contrast to the increase in IL-6 we have
reported, the cytokines IL-1b and IFN-g were not
altered in response to chronic hypoperfusion or DMF
treatment. IL-1b is increased after focal cerebral ischae-
mia87 and promotes neuronal damage. Although we did
not detect any alterations in IL-1b, others have
reported that levels of IL-1b appear to alter transiently
at different time points in response to differing extents
of cerebral hypoperfusion.16,88 We also reported no
alterations in IFN-g levels, which concurs with a find-
ings in focal cerebral ischaemia.89 Collectively, there
was minimal evidence that DMF could modulate
cytokine levels, whereas modest effects were seen on
MIP-1a.
Given the modest protective effects of DMF that we
have reported seven days following severe hypoperfu-
sion, it would be interesting to study longer term time
points. Miki et al.15 showed that severe hypoperfusion
causes progressive white matter pathology and we have
previously reported that more modest decreases in cere-
bral blood flow cause increased microgliosis and altered
axon-glial integrity at one month,8,9 that progresses to
include microinfarcts, haemorrhage and blood–brain
barrier alterations. DMF is reported to reduce ischae-
mic neuronal death, oedema and blood–brain barrier
breakdown36,64,75 in the acute response to focal cerebral
ischaemia thus may have protective effects in the
chronic response to modest blood flow reduction.
DMF is reported to have protective effects following
long-term administration in EAE,40,41 Parkinson’s dis-
ease,32 and following one year of administration in a
mouse model of Huntington’s disease.29
To conclude, we have demonstrated that severe
hypoperfusion caused deficits in white matter function
and that DMF improved white matter function follow-
ing severe hypoperfusion. Although there was no effect
of DMF on the structural integrity of damaged myelin-
ated axons, DMF had modest effects on microglia/
macrophages.
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